Oct 13, 2009 1
novel agents and treatment of advanced NSLC
Integration of Novel Agents Into Treatment Regimens for Patients With Advanced Non-Small-Cell Lung Cancer
Treatment options in non-small-cell lung cancer (NSCLC) have expanded recently due to the demonstration of efficacy of targeted agents alone or in combination with existing cytotoxic chemotherapies. Research with these approaches is ongoing, and the 2006 American Society of Clinical Oncology meeting featured presentations from studies of epidermal growth factor (EGFR) inhibitors and antiangiogenic agents, as well as on the use of other novel compounds. Read the rest of this entry »
Most Commented